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Abstract
Background
Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coro-
nary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with
high residual platelet reactivity (HRPR) i.e. poor responders, is limited.
Objectives
To determine the effects of prasugrel loading on platelet function in patients on clopidogrel
and high platelet reactivity undergoing percutaneous coronary intervention for acute coro-
nary syndrome (ACS).
Patients
Patients with ACS on clopidogrel who were scheduled for PCI found to have a platelet reac-
tivity40 AUC with the Multiplate Analyzer, i.e. “poor responders” were randomised to pra-
sugrel (60 mg loading and 10 mg maintenance dose) or clopidogrel (600 mg reloading and
150 mg maintenance dose). The primary outcome measure was proportion of patients with
platelet reactivity <40 AUC 4 hours after loading with study medication, and also at one hour
(secondary outcome). 44 patients were enrolled and the study was terminated early as clo-
pidogrel use decreased sharply due to introduction of newer P2Y12 inhibitors.
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Results
At 4 hours after study medication 100% of patients treated with prasugrel compared to 91%
of those treated with clopidogrel had platelet reactivity <40 AUC (p = 0.49), while at 1 hour
the proportions were 95% and 64% respectively (p = 0.02). Mean platelet reactivity at 4 and
1 hours after study medication in prasugrel and clopidogrel groups respectively were 12 ver-
sus 22 (p = 0.005) and 19 versus 34 (p = 0.01) respectively.
Conclusions
Routine platelet function testing identifies patients with high residual platelet reactivity
(“poor responders”) on clopidogrel. A strategy of prasugrel rather than clopidogrel reloading
results in earlier and more sustained suppression of platelet reactivity. Future trials need to
identify if this translates into clinical benefit.
Trial Registration
ClinicalTrials.gov NCT01339026
Introduction
Dual antiplatelet therapy (DAPT) consisting of aspirin and an adenosine diphosphate (ADP)
receptor inhibitor has been shown to reduce the risk of subsequent vascular events including
myocardial infarction (MI) and stent thrombosis in patients with acute coronary syndromes
(ACS).[1] Some of the benefits of DAPT for ACS patients undergoing percutaneous coronary
intervention (PCI) appear to be related to pre-treatment with a loading dose of the ADP-recep-
tor blocker clopidogrel.[2] In a substantial proportion of patients clopidogrel is associated with
poor antiplatelet response [3] probably due to restriction of bioavailability and inter patient
variation due to phenotype or genotype. Although prasugrel and ticagrelor exhibit faster onset
of action and reach better clinical outcomes with enhanced platelet inhibition prior to PCI, the
majority of patients continue to receive clopidogrel as reported in the European registry
APTOR [4]. Clopidogrel has shortcomings with slow onset of action and high variability of
platelet inhibition caused by genetically defined poor metabolism leading to more than half of
patients exhibiting continued high platelet reactivity at the time of PCI, despite a timely admin-
istered high dose loading.[5] High platelet reactivity is associated with a higher risk of throm-
botic events.[6] Accordingly we established the APACS HPR (Additional Platelet inhibition in
Acute Coronary Syndromes with High Platelet Reactivity) trial to measure the effects on plate-
let function of an additional loading dose of prasugrel, or clopidogrel, in patients with ACS
scheduled for PCI who had been started on clopidogrel but had high platelet reactivity (“poor
responders”).
Methods
Study Design
APACS was a randomised, open label study carried out in 1 centre in Germany and 4 centres
in the UK comparing prasugrel with clopidogrel reloading in ACS patients pre-treated with
clopidogrel who had high residual platelet reactivity (“poor responders”). PCI had to be
planned to take place as early as possible and no later than 72 hours from admission.
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Patients with prior clopidogrel loading within 24h before planned PCI or receiving chronic
treatment with clopidogrel (e.g. for>24 hours having received at least one previous 600 mg
loading dose with subsequent 75 mg maintenance dose, or7 days of maintenance therapy)
who had high platelet reactivity 40 AUC were randomised to prasugrel (60 mg loading and
10 mg maintenance dose) or a high dose clopidogrel regimen (600 mg reloading followed by
150 mg maintenance dose). There are no large clinical endpoint studies evaluating cut-off val-
ues for platelet reactivity measured with Multiplate Analyzer in the early phase e.g. 4h after
loading dose in ACS patients to predict early periprocedural events. 40 AUC was a prespecified
arbitrary cut-off value based on previous observations, showing that a similar degree of platelet
reactivity can be achieved at ~4h after loading with newer platelet inhibitors prasugrel and tica-
grelor. [7] APACS was an open-label trial. The laboratory assistant performing the platelet
function analysis was blinded to the allocation arms. Flow diagram of the study is shown in
Fig 1, diagram of randomisation process in Fig 2.
Fig 1. Consort flow diagram of the trial.
doi:10.1371/journal.pone.0135037.g001
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Screened patients identified with low platelet reactivity indicating a good response to clopi-
dogrel were entered into a registry. The trial was registered at clinicaltrial.gov (NCT01339026).
The APACS study was conducted in compliance with the principles of the Declaration of Hel-
sinki and the International Conference on Harmonization consolidated guidelines and was
approved by the NHS Research Ethics Committee and the ethical review committees of
Tübingen University. Patients gave written informed consent prior to study participation.
Patients
Inclusion criteria were: ACS, age: 18–75 years, intention to perform PCI<72 hours from
admission, prior or chronic treatment with clopidogrel (defined as prior clopidogrel loading
within 24h before planned PCI or chronic>24 hours and at least 7 days of maintenance dose
treatment with clopidogrel), high platelet reactivity as defined by ADP induced platelet activa-
tion of 40 AUC by Multiplate analyser with timing of platelet function assay at least 2 hours
after pre-PCI loading dose, provision of informed consent by participating patient. Inclusion
criteria for the registry were the same as above except for a platelet reactivity of<40 AUC.
Exclusion Criteria were body weight<60 kg, pre-treatment with prasugrel within 7 days of
randomisation, history of stroke or transient ischemic attack, patients with increased bleeding
Fig 2. Diagram of inclusion and randomisation process (Abbreviations: BARC: Bleeding Academic Research Consortium; LD: Loading Dose,
MACE: major adverse cardiovascular events, MEA: Multiple Electrode Aggregometry; PR: Platelet reactivity, TP: Time point, P.D.: Physician’s
Discretion).
doi:10.1371/journal.pone.0135037.g002
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risk e.g. recent major trauma or surgery, gastrointestinal bleeding or active peptic ulceration,
platelet count< 100 x109/L at the time of screening, International Normalized Ratio (INR)>
1.5 at the time of screening, Hb<10g/dL, intracranial neoplasm, arteriovenous malformation
or aneurysm, severe hepatic impairment (Child Pugh class C) or intention to use the following
medications: oral anticoagulation, other antiplatelet therapy (including GPIIb/IIIa inhibitors)
besides aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-
2) inhibitors, female patients who are pregnant, planning pregnancy, or who are breastfeeding,
known allergy, hypersensitivity or other contraindications to prasugrel or clopidogrel or hemo-
dynamically unstable patients in whom study related procedures might cause unnecessary
delays to urgent revascularization.
Impedance platelet aggregometry
The Multiplate analyzer, a whole blood platelet function assay, was used to study the platelet
aggregation level. A 600μL blood sample acquired in hirudinized tubes (Sarstedt) was obtained
to perform ADP and TRAP tests in each patient. The blood samples were taken before the
loading dose, 1h, 4 hours and 24h after the loading dose. The area under the aggregation curve
(AUC) was used as a measure of the overall platelet aggregation. Tests were performed 30 min-
utes to 3 hours after taking blood.
Randomisation and treatment schedule
Patients were randomised to either open label clopidogrel (600 mg additional loading dose, fol-
lowed by 150 mg daily maintenance dose for 7 days, followed by 75 mg daily for up to 12
months) or prasugrel (60 mg additional loading dose, followed by 10 mg daily). The randomi-
sation algorithm is presented in Fig 2. Randomisation blocks were generated by the responsible
statistician (Winston Banya) and sent to Sealed Envelope for the web based randomisation
database. The investigator or his/her designee accessed the randomisation service and the ran-
domisation allocation was released after eligibility criteria were confirmed and informed con-
sent had been obtained. Each randomised patient was assigned a unique identifying number.
The web based database system sent automatic email confirmation of randomisation to autho-
rised personnel.
Follow Up
Randomised patients were followed up to 30 days for clinical status, study medication, blood
samples for adenosine diphosphate ADP) and thrombin receptor activating peptide (TRAP)
test and serious adverse events (SAEs). Registry patients were followed up to 30 days for sur-
vival. Major Adverse Cardiac Events (MACE) were defined as death, stroke, myocardial infarc-
tion and repeat revascularization. Bleeding events were defined according to the bleeding
academic research consortium criteria (BARC) criteria as previously reported.[8]
Primary endpoint was the proportion of patients with improved platelet response i.e. plate-
let reactivity under the cut-off value of 40 AUC in the prasugrel reloading arm compared to the
clopidogrel reloading arm at 4 hours after randomisation in patients with initial high platelet
reactivity.
The secondary endpoints were ADP induced platelet reactivity at 1 and 24 hours, TRAP
induced platelet reactivity at 1, 4 and 24 hours, and MACE including death, stroke, myocardial
infarction, repeat revascularization and major bleedings defined according to BARC.
PFT-Guided DAT in ACS Patients Undergoing PCI
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Statistical analysis
For an absolute difference of 20% in conversion of patients with initial high platelet reactivity
to a platelet reactivity under the cut-off value of<40 AUC (i.e. reduction of prevalence from
30% to at least 10%) after reloading with prasugrel compared to clopidogrel the estimated min-
imum sample size was 62 patients per arm (80% power at a two-sided alpha value of 5%) to
detect this difference. Baseline variables were compared with the use of chi-square tests for cat-
egorical variables; t-tests were used for normally distributed continuous variables and the Wil-
coxon rank-sum for variables with non-Gaussian distributions. Comparison of the primary
endpoint and secondary endpoints was carried out using a chi squared or Fishers exact test.
The confidence intervals were two-sided with a 95% confidence level, and all hypothesis tests
were two-sided carried out at a significance level of 0.05.
Results
The study started enrolment in February 2012. During the course of the trial clinicians had
started to adopt clinical guidelines recommending prasugrel or ticagrelor over clopidogrel for
ACS patients.[9,10] which decreased the use of clopidogrel. A decision was therefore made by
the APACS Investigators group to terminate recruitment on the 31st July 2013 well before the
predicted recruiting time, so that only 44 patients could be recruited.
Of the ACS cohort 40.7% was found to have HRPR at the time of PCI despite pre-treatment
with clopidogrel. 44 patients fulfilled all eligibility criteria, consented to study participation and
were enrolled. Another 64 patients fulfilled eligibility criteria but had normal platelet reactivity
(i.e.<40 AUC) and entered the registry (Fig 1). The baseline characteristics of randomised and
screened patients are shown in Table 1. Patients with high platelet reactivity versus normal
Table 1. Baseline characteristics in the randomised patients versus screened patients. Abbreviations: LBBB: left bundle branch block, RBBB: right
bundle branch block, BMI: body mass index.
Variable Randomised (n = 44) Registry (n = 64) P
Age–mean (SD) 59.6 (9.2) 62.3 (9.6) 0.15
Gender—Male 38 (86.4) 46 (71.9) 0.08
BMI–mean (SD) 29.2 (5.4) 28.4 (3.9) 0.43
Ethnicity: White European South Asian/ other : 40/44 (91): 4/44 (9) : 63/63 (100): 0/63 (0)
systolic blood pressure: –mean (SD) 138 (24) 134 (20) 0.32
diastolic blood pressure: –bmean (SD) 76 (13) 75 (12) 0.81
Heart rate–mean (SD) 71 (19) 70 (11) 0.73
Heart Rhythm: Sinus rhythm: Atrial fibrillation: Paced:
Other
: 39 (88.64): 2 (4.55): 1 (2.27): 2
(4.55)
: 61/63 (96.83): 1/63 (1.59): 0: 1/63 (1.59) 0.25
ECG Changes: No change: T Wave Inversion: ST
Depression: ST Elevation: LBBB:: RBBB: Other
changes
: 13 (29.55): 18 (36.36): 1 (2.27): 3
(6.82): 2 (4.55): 1 (2.27): 8
(18.18)
: 26/63 (41.27): 18/63 (28.57): 9/63 (14.29):
7/63 (11.11): 2/63 (3.17): 1/63 (1.59): 0
Hypertension 30 (68.2) 35/62 (56.45) 0.22
Hypercholesterolemia 27 (61.4) 26/63 (41.27) 0.04
Diabetes 18 (40.9) 14/63 (22.22) 0.038
Prior MI 15 (34.1) 14 (21.88) 0.16
Prior PCI 22/43 (51.2) 18 (28.13) 0.016
Smoking history: None:: Ex: Current :: 7/28 (25.0): 14/28 (50.0): 7/28
(25.0)
: 15/43 (34.88): 14/43 (32.56): 14/43
(32.56)
0.34
Loading Platelet reactivity: –mean (SD) 57.6 (15.7) 21.2 (10.6) < 0.0001
Type of admission Ambulance Elective: Transfer from
other hospital: Other
:: 31 (70.45): 7 (15.91): 6 (13.64): 0 :: 33 (51.56): 4 (6.25): 25 (39.06): 2 (3.13) 0.007
doi:10.1371/journal.pone.0135037.t001
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platelet reactivity were more often hypercholesterolemic or diabetic. The mean age of the ran-
domised patients was 59.7 years and 86% (n = 38) were male. Severe angina (CCS class III or
IV) was present in 39% (n = 17) of patients. 41% (n = 18) had diabetes, 34% (n = 15) had a
prior myocardial infraction (MI) and 51% (n = 22) had a prior PCI (Table 1). Baseline charac-
teristics of demographic and clinical parameters were well balanced between randomisation
arms (Table 2). Baseline mean platelet reactivity was 57.6 AUC in both groups as shown in
Table 3. The proportion of patients who changed from ADP 40 AUC to< 40 AUC are
shown in Table 3 and the change over time is shown in Fig 3. Mean values for platelet aggrega-
tion over time are shown in Fig 3 confirming that prasugrel was more effective in reducing
platelet aggregation. For the primary outcome analysis at 4 hours post loading with the study
drug there was no significant difference between the groups, p = 0.49. Nevertheless, at 1 hour
post loading with prasugrel 95% of patients had<40 AUC compared to 64% in the clopidogrel
group (p = 0.022). The change in platelet reactivity (from clopidogrel to prasugrel) at 1 hour
was 14.85 AUC (95% CI 3.64, 26.05, p = 0.01) and at 4 hours was 10.26 AUC (95% CI 3.29,
17.24, p = 0.005).
With respect to TRAP induced platelet aggregation there was a significant difference at
baseline between both arms. Patients randomised to prasugrel had lower TRAP induced
Table 2. Baseline characteristics according to randomisation arms.
Variable Prasugrel (n = 22) Clopidogrel (n = 22) p
Age: mean (SD) 60.9 (9.9) 58.5 (8.5) 0.39
Gender–Male 19/22 (86.4) 19/22 (86.4) 1.00
BMI: mean (SD) 29.0 (4.4) 29.3 (6.4) 0.87
systolic blood pressure: –mean (SD) 141 (28) 135 (19) 0.40
diastolic blood pressure: –mean (SD) 74 (14) 78 (12) 0.51
Heart rate–mean (SD) 72 (20) 71 (18) 0.78
CCS Class: 0:: I: II:: III: IVa : 7/20 (35.0): 1/20 (5.0): 1/20
(5.0): 1/20 (5.0): 10/20 (50.0)
:: 5/16 (31.25): 3/16 (18.75): 2/18 (12.50): 1/16
(6.25): 5/16 (31.25)
0.58
NYHA Class: I: II: III : 13/22 (59.09): 7/22 (31.82): 2/
22 (9.09)
:: 8/16 (50.00): 5/16 (31.25): 3/16 (18.75) 0.73
Heart Rhythm: Sinus rhythm: Atrial fibrillation: Paced:
Other
: 20/22 (90.90): 1/22 (4.55): 1/22
(4.55): 0/22
: 19/22 (86.36): 1/22 (4.55): 0/22: 2/22 (9.09) 0.74
ECG Changes: No change: T Wave Inversion: ST
Depression: ST Elevation: LBBB: RBBB: Other
changes
: 8/22 (36.36): 9/22 (40.91): 0: 0:
1/22 (4.55): 0: 4/22 (18.18)
:: 5/22 (22.73): 7/22 (31.82): 1/22 (4.55): 3/22
(13.64): 1/22 (4.55): 1/22 (4.55): 4/22 (18.18)
0.45
ACS type: STEMI: NSTEMI: Unstable Angina : 0 (0): 8 (36.4): 14 (53.8) :: 3 (13.6): 7 (31.8): 12 (54.5) 0.32
Hypertension 14/22 (63.6) 16/22 (72.7) 0.52
Hypercholesterolemia 12/22 (55.6) 15/22 (68.2) 0.35
Diabetes 11/22 (50.0) 7/22 (31.8) 0.22
Prior MI 7/22 (31.8) 8/22 (36.4) 0.75
Prior PCI 11/22 (50.0) 11/21 (52.4) 0.87
Hb (mg/dL)–mean (SD) 14.4 (1.4) 14.2 (1.4) 0.69
Platelet count x1000/microL: –mean (SD) 24.4 (6.7) 27.5 (5.5) 0.12
Creatinine (mg/dl): –mean (SD) 86.8 (29.8) 78.0 (19.1) 0.27
Beta Blockers 17/22 (77.3) 13/22 (59.1) 0.20
ACE Inhibitors 9/22 (40.9) 12/22 (54.6) 0.37
Aspirin:: In Ambulance: On Arrival: Before admission : 7/20 (35.0): 9/20 (45.0): 4/20
(20.0)
:: 7/19 (36.84): 12/19 (63.16): 0 0.15
Statins 13/22 (59.09) 15/22 (68.18) 0.53
doi:10.1371/journal.pone.0135037.t002
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platelet aggregation compared to patients allocated to clopidogrel reloading (mean 98.6 AUC
95%CI 89.8, 101.4 vs mean 108.1 AUC 95%CI 96.5, 119.7; p = 0.02). The reduced TRAP
induced aggregation values in the prasugrel compared to the clopidogrel treated arm persisted
over time mean 66.9 AUC (95%CI 58.3, 75.5) vs. mean 78.9 AUC (95%CI 69.4, 88.3) at 1 hour,
mean 63.0 AUC (95%CI 55.6, 70.4) vs. mean 67.4 (95%CI 58.8, 76.0, p = 0.23) at 24 hours;
(Table 4).
Clinical events are shown in Table 5. There were no deaths. In the prasugrel group, there
was 1 MI, and 1 repeat revascularization reported. In the clopidogrel group there were 1 stroke
and 1 repeat revascularization. In the prasugrel group there were 1 BARC major bleed type 3b
and 2 BARC minor bleeds type 1. In the clopidogrel group there was 1 major bleed (Cerebro-
vascular accident) and no minor bleeds were reported.
Discussion
The primary endpoint of the proportion of patients with platelet reactivity under the cut-off
value of 40 AUC after randomisation was not significantly different in the prasugrel reloading
arm compared to the clopidogrel reloading arm at 4 hours although this analysis lacks statisti-
cal power due to early termination. In the secondary analysis, reloading with prasugrel pro-
vided a better antiplatelet response at one hour than reloading with clopidogrel. The findings
can be explained by the greater antiplatelet efficacy and faster onset of prasugrel shown in
mechanistic studies and better clinical outcomes as seen in TRITON-TIMI38. However a direct
comparison of these two agents in clopidogrel “poor responders” in the setting of ACS and PCI
has not been carried out.
Poor platelet inhibition in the early phase of ACS and PCI is associated with MACE includ-
ing acute stent thrombosis.[11] In a recent meta-analysis of randomised controlled trials reduc-
ing high platelet reactivity in ACS was associated with a reduction of major ischemic
complications.[12] Prasugrel achieves higher platelet inhibition compared to clopidogrel in
pharmacodynamic analyses in healthy volunteers and stable CAD patients.[13,14] In TRI-
TON-TIMI38 prasugrel was compared to clopidogrel 300mg in P2Y12 inhibitor naïve patients.
To date there is no data from randomised trials comparing the peri-procedural effects of
prasugrel versus high dose clopidogrel in thienopyridine pre-treated ACS patients which is a
common clinical scenario. In fact, randomised studies investigating pharmacodynamic/
Table 3. Multiplate results. ADP-Test of randomised patients at different time points before and after randomisation. Number of patients with high and low
platelet reactivity in every arm are presented according to time and the mean platelet reactivity in AUC for each arm are presented
Time point of Multiplate Patients in the Prasugrel arm (n = 22) Patients in the Clopidogrel arm (n = 22) Total patients (n = 44) p
t0: Loading dose administration
 40 AUC 20/21 (95.24) 21/22 (95.45) 41/43 (95.35)
: 1.00
< 40 AUC 1/21 (4.76) 1/22 (4.55) 2/43 (4.65)
t1: 1 Hour Post Loading Dose (secondary outcome)
 40 AUC 1/20 (5.0) 8/22 (36.36) 9/42 (21.43)
: 0.022
< 40 AUC 19/20 (95.0) 14/22 (63.64) 33/42 (78.57)
t2: 4 Hour Post Loading Dose (primary outcome)
 40 AUC 0/20 2/22 (9.09) 2/42 (4.76)
: 0.49
< 40 AUC 20/20 (100.0) 20/22 (90.91) 40/42 (95.24)
Comparison of mean platelet reactivity (AUC)
Loading dose 57.6 (50.2, 65.0) 57.6 (50.7, 64.5) 57.58 (52.76, 62.41) 1.00
1 h post loading dose 19.2 (9.9, 28.5) 34.0 (26.9, 41.2) 26.98 (20.98, 32.97) 0.010
4 h post loading dose 12.1 (9.2, 15.0) 22.4 (16.1, 28.7) 17.48 (13.68, 21.27) 0.005
24 h post loading dose 12.7 (8.8, 16.8) 19.5 (13.8, 25.2) 16.1 (12.5, 19.6) 0.049
doi:10.1371/journal.pone.0135037.t003
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pharmacokinetic profile suggest that even with the third generation P2Y12 inhibitors prasugrel
and ticagrelor, the platelet inhibitory effect in real world ACS patients is insufficient at the time
of the procedure.[15,16] This effect might be partly caused by the higher degree of platelet acti-
vation and aggregation in the setting of an acute coronary event and partly because of response
variability due to genetic and clinical factors also seen with 3rd generation P2Y12 receptor
blockers. On the other hand, early and potent platelet inhibition by prasugrel loading in the
upstream period has been associated with an excess of procedural related major bleedings with-
out ischemic risk reduction in the ACCOAST trial.[17] It is therefore tempting to speculate
that a peri-procedural therapeutic window of platelet inhibition in NST-ACS patients exists as
previously suggested in a recent consensus statement.[18]
The present findings suggest that early prasugrel reloading in clopidogrel pre-treated ACS
patients who exhibit high platelet reactivity at the time of PCI may provide a more rapid and
complete maximum platelet inhibition compared to reloading with 600mg clopidogrel fol-
lowed by a high dose clopidogrel maintenance dose regimen. The study further indicates that
about 40% of patients have high platelet reactivity at the time of PCI despite adequate
Fig 3. Pharmacodynamic profile showing ADP induced platelet aggregation over time according to treatment arms.
doi:10.1371/journal.pone.0135037.g003
Table 4. TRAP-Test results at different time points before and after randomisation (Mean platelet reactivity (95%CI).
Time point of Multiplate TRAP-test in the Prasugrel arm TRAP-test in the Clopidogrel arm Mean TRAP-test result P
Loading dose 88.2 (75.5, 100.8) 108.1 (96.5, 119.7) 98.6 (89.8, 101.4) 0.02
1 h post loading dose 53.8 (40.7, 66.8) 78.9 (69.4, 88.3) 66.9 (58.3, 75.5) 0.002
4 h post loading dose 53.9 (43.1, 64.8) 65.4 (55.8, 75.0) 60.1 (53.0, 64.2) 0.11
24 h post loading dose 58.6 (46.0, 71.2) 67.4 (58.8, 76.0) 63.0 (55.6, 70.4) 0.23
doi:10.1371/journal.pone.0135037.t004
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clopidogrel pre-treatment. This observation corresponds well with previous reports of up to
50% of NSTE-ACS5 and 64.5% of STEMI patients [19] expressing high platelet reactivity after
a 600mg clopidogrel-loading dose at the time of PCI.
Whereas the benefit of platelet function test guided antiplatelet therapy for the post-ACS
long-term phase has been debated [20,21], there are few studies focusing on this concept in the
early, critical phase of an ACS. Bonello investigated the impact of the Vasodilator-stimulated
phosphoprotein (VASP) assay and showed that a platelet function testing guided multiple
loading regimen was superior to standard therapy in the early ACS phase.[22] Few studies to
date have addressed the impact of switching thienopyridine therapy in clopidogrel-pre-treated
patients. In healthy subjects, switching from maintenance clopidogrel dosing to prasugrel with
additional 60mg loading dose led to a more pronounced platelet inhibition.[23] Likewise, in
the Switching Anti Platelet (SWAP) study, switching to prasugrel improved platelet inhibition
within 2 hours after additional prasugrel loading dose in patients on clopidogrel maintenance
therapy in patients with a previous acute coronary event. However, in the latter study the mean
time interval between event and study entry ranged from 77.4 to 102.2 days depending on the
treatment arm.[24]
To the best of our knowledge, there are no data from randomised clinical trials investigating
the role of platelet function testing using multiple impedance aggregometry in the very early
procedural time window in ACS patients. The present results suggest that preselecting patients
might help to improve platelet inhibition in this critical phase of an acute coronary event. In
the present study, repeated clopidogrel loading dose regimen was not sufficient to overcome
high platelet reactivity in ACS patients. This is in line with previous results from pharmacody-
namic studies in stable CAD patients. A high dose clopidogrel regimen was only able to reduce
high platelet reactivity in non-carriers of the loss-of-function CYP2C192 genotype in contrast
to prasugrel.[25,26]
Limitations
This trial has some limitations. First of all it was prematurely terminated due to changing
guideline adherence and before the calculated sample size for the primary endpoint was
reached. The active comparator of high dose clopidogrel is not favoured by current guidelines.
However, due to current treatment patterns and lack of evidence and safety concerns of novel
P2Y12 receptor antagonist in the upstream period of NSTE-ACS, clopidogrel is still widely used
in the ambulance setting and the majority of NSTE-ACS patients in Europe and North Amer-
ica are still pre-treated with clopidogrel. This will likely persist due to higher costs for newer
antiplatelet agents. We did not evaluate the impact of the loss- or gain of function genotypes
that might have influenced metabolism of the P2Y12 receptor antagonists in particular
Table 5. Patients with MACE or Bleedings.
Events Prasugrel (n = 22) Clopidogrel (n = 22)
MACE
Death 0 0
Myocardial Infarction 1 0
Cerebral Vascular Accident 0 1
Revascularization 1 1
Bleeds (BARC definition)
Major 1 1
Minor 2 0
doi:10.1371/journal.pone.0135037.t005
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clopidogrel in the acute setting.[27] The concept of genotype-guided antiplatelet therapy is cur-
rently debated and not recommended on a routine level.[28,29] The study was not powered for
assessment of clinical events and the safety of a platelet function guided approach to reload
with prasugrel remains to be investigated in trials that are sufficiently powered to assess for
bleeding events. Nevertheless, recent data from a non-randomised, retrospective study sup-
ports the feasibility and safety of a prasugrel reloading regimen in ACS patients pre-treated
with clopidogrel.[30]
Conclusions
In conclusion our data provides evidence that residual high platelet reactivity can be corrected
by prasugrel in patients with ACS undergoing PCI who have been treated with clopidogrel.
The role of platelet function testing is evolving and is not currently recommended as a routine
test in guidelines [8,9] while it remains a relevant feature in studies specifically testing anti-
platelet response to therapy (e.g. clinicaltrials.gov NCT01959451). Given that clopidogrel con-
tinues to be the most commonly used antiplatelet agent in Europe, our data provides further
support for clinical studies in health systems that routinely use clopidogrel for the management
of ACS. A targeted use of more potent and more effective antiplatelet agents guided by platelet
function testing may be warranted with the aim of reducing recurrent ischemic events after
ACS, however this should be evaluated in larger randomised studies.
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